Xenetic Biosciences, Inc. (XBIO) Issues Quarterly Earnings Results
Xenetic Biosciences, Inc. (NASDAQ:XBIO) posted its quarterly earnings data on Monday. The company reported ($0.34) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.21) by $0.13, Bloomberg Earnings reports.
Xenetic Biosciences (XBIO) remained flat at $2.55 during trading on Wednesday. 70 shares of the company’s stock were exchanged. Xenetic Biosciences has a 52 week low of $2.55 and a 52 week high of $37.62. The firm’s market cap is $22.23 million. The company has a 50 day moving average price of $2.87 and a 200 day moving average price of $3.64.
Separately, Zacks Investment Research downgraded shares of Xenetic Biosciences from a “hold” rating to a “sell” rating in a report on Wednesday, May 24th.
WARNING: This piece was originally published by Watch List News and is owned by of Watch List News. If you are accessing this piece on another site, it was illegally stolen and republished in violation of U.S. and international trademark and copyright legislation. The correct version of this piece can be read at https://www.watchlistnews.com/xenetic-biosciences-inc-xbio-issues-quarterly-earnings-results/1495022.html.
Xenetic Biosciences Company Profile
Xenetic Biosciences, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the research and development of certain pharmaceutical products for use in humans that includes the use of the Company’s platform technologies that enables the creation of drug therapies primarily for orphan indications.
Receive News & Ratings for Xenetic Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenetic Biosciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.